KCC2 Expression Enhancing Compounds for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Rett syndrome and related neurological disorders, such as autism spectrum disorders, are inadequate due to unsatisfactory efficacy in restoring the balance between excitatory and inhibitory neurotransmission, which is crucial for brain function and is disrupted in these conditions.
Innovation Solution
A novel screening platform using genome-edited reporter neurons to identify potassium chloride cotransporter-2 (KCC2) expression enhancing compounds (KEECs), which can enhance KCC2 expression and potentially treat Rett syndrome and other neurological disorders by modulating the molecular pathways involved in neurotransmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat Rett syndrome and neurological disorders, then treatment is provided, but efficacy in restoring excitatory-inhibitory neurotransmission balance is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from general pathway modulation to specific KCC2 expression enhancement. By identifying compounds that directly increase KCC2 protein levels through modified cell-permeable peptides, the therapy targets the specific molecular deficit in RTT neurons, thereby improving reliability of neurotransmission balance restoration.
Solution Approach 2:
The patent introduces KCC2 expression-enhancing compounds as intermediary agents between the administered therapy and the dysfunctional neural pathways. These compounds act as mediators that specifically upregulate KCC2 expression in neurons, bridging the gap between general treatment approaches and precise correction of GABAergic signaling deficits.
2Reliability
If X chromosome reactivation is attempted to restore MECP2 expression, then MECP2 levels may be increased, but oncogenic transformation risk increases
Solution Approach 1:
The patent extracts the therapeutic benefit (KCC2 upregulation) from the problematic approach (X chromosome reactivation). Instead of attempting to reactivate the entire X chromosome to restore MECP2, the invention directly targets KCC2 expression enhancement through specialized peptides, separating the useful outcome from the harmful genomic instability risks.
Solution Approach 2:
The patent converts the known deficit in KCC2 expression (a harmful factor in RTT pathogenesis) into a therapeutic target. By designing compounds that specifically enhance KCC2 levels, the invention transforms the molecular weakness into a point of intervention, achieving benefit without triggering the oncogenic risks associated with broader genomic manipulations.
3Adaptability or versatility
If broad molecular pathways are modulated to treat RTT symptoms, then multiple downstream targets are affected, but treatment efficacy remains unsatisfactory
Solution Approach 1:
The patent segments the broad molecular pathway modulation approach into a highly specific intervention. Instead of affecting multiple downstream targets through general pathway modulation, the invention uses modified cell-permeable peptides to specifically enhance KCC2 expression, isolating the therapeutic action to the precise molecular target responsible for GABAergic signaling deficits.
Solution Approach 2:
The patent applies local quality by concentrating therapeutic effect specifically at the KCC2 protein level in neurons. The modified cell-permeable peptides are designed to selectively enhance KCC2 expression in neural tissue, providing localized, high-quality therapeutic action rather than broad, diffuse pathway modulation, thereby improving efficacy through precision.
Data Source
AI summary
Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice. These first-in class compounds may be applied as a novel therapeutic approach to restore the impaired balance between excitation and inhibition observed in neurological diseases, psychiatric disorders, and central nervous system injuries.